SeekingAlpha · Sep 15, 2026
Vaxart, Inc. (VXRT) Presents at H.C. Wainwright 28th Annual Global Investment Conference - Slideshow
2026-09-15. The following slide deck was published by Vaxart, Inc.
VX
OTC · VXRT
VAXART INC
Healthcare · Biotechnology
$0.44
Up+$0.01 (+1.85%)
Updated Oct 8, 2026, 1:55 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 87.55M
- P/E ratio
- -1.65
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 1.1K
- Avg. volume
- 545.48K
Price performance · VXRT
VXRT price history
1M range · 0 trading sessions · Daily adjusted prices
VXRT does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest VXRT news
The latest Smart Investors Daily articles mentioning VXRT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
VXRT research
Overview
Company profile and research snapshot.
Company profile
VAXART INC
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 27, 2025 | B. Riley Securities | Buy | — |
| Aug 15, 2024 | Oppenheimer | Outperform | — |
| Jan 31, 2024 | B. Riley Securities | Buy | — |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | — |
| Aug 7, 2023 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 15, 2026
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference
Vaxart (OTCMKTS:VXRT) Chief Executive Officer Steve Lo outlined the company’s oral vaccine platform, its government-funded COVID-19 study and development opportunities in norovirus and influenza during an H.C. Wainwright conference presentation. Lo said Vaxart’s recombinant adenovirus type 5, or Ad
Yahoo · Sep 8, 2026
Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that a member of its management team will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026. H.C. Wainwright 28th Annual Global Investment ConferenceDate: Monday, September 14Time: 1:00 p.m. – 1:30 p.m.
SeekingAlpha · Aug 31, 2026
Vaxart, Inc. (VXRT) Q2 2026 Stockholder Fireside Chat Call Transcript
Vaxart (VXRT) Q2 2026 update: positive 12-month safety data for oral COVID pill vs mRNA
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
